AOD-9604 vs Dulaglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
AOD-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. The idea was to keep the fat-burning end of growth hormone while leaving out the part that raises IGF-1 or messes with blood sugar. It was developed by Metabolic Pharmaceuticals in Australia and tested as an anti-obesity drug, but it is not approved by the FDA or any major regulator, and development stopped after it missed its weight-loss targets.
Also: Trulicity
Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Key Comparison Insights
- Dulaglutide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Dulaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | In lab and animal studies, AOD-9604 appears to nudge fat cells toward breaking down stored fat (lipolysis) and away from making new fat (lipogenesis), echoing the lipolytic tail-end of the full growth hormone molecule. Unlike real growth hormone, it does this without meaningfully raising IGF-1, the downstream growth signal that drives growth hormone's anabolic and blood-sugar effects. The exact receptor it works through is not pinned down, and a clean, growth-hormone-receptor-independent pathway remains a working hypothesis rather than settled science. In short, the proposed selling point is fat-burning signaling without the classic growth hormone baggage, but the molecular details are still fuzzy. | Dulaglutide activates the GLP-1 receptor, mimicking the natural incretin hormone your gut releases after eating. It prompts glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, so blood sugar drops after meals without driving dangerous lows. The antibody (Fc) portion bolted onto the peptide makes the molecule too large for the kidneys to quickly clear and shields it from the DPP-4 enzyme that destroys natural GLP-1 within minutes. That engineering is the entire reason a once-weekly schedule works. The appetite and modest weight effects come from the same GLP-1 signaling in brain regions that regulate hunger. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 1.5-4.5 mg weekly Once weekly |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal and cell data look encouraging, but the human story is where it falls apart. Across roughly six randomized, double-blind, placebo-controlled trials involving about 900 people, a safety review published in the Journal of Endocrinology and Metabolism (Moré et al.) found AOD-9604 was well tolerated, did not raise IGF-1, did not harm glucose metabolism, and triggered no detectable antibodies. The catch: it did not deliver clinically meaningful weight loss. The largest Phase IIb obesity trial failed to beat placebo on its main endpoint, and Metabolic Pharmaceuticals halted clinical development around 2007. So the honest summary is a peptide with a clean safety record in humans and essentially no proven efficacy for fat loss in humans. | Dulaglutide is backed by extensive human trials, not animal models. The AWARD program established its glucose-lowering efficacy across many type 2 diabetes settings. The landmark REWIND trial, published in The Lancet in 2019, followed over 9,900 patients for a median of more than five years and was unusual because most participants (about 69%) had no prior cardiovascular disease. It found dulaglutide reduced major cardiovascular events (cardiovascular death, heart attack, or stroke) versus placebo, 12.0% vs 13.4%, a hazard ratio of 0.88. That made it one of the first GLP-1 agents with evidence supporting both primary and secondary cardiovascular prevention. The typical downsides are gastrointestinal (nausea, diarrhea), and like others in the class it carries a boxed warning about thyroid C-cell tumors based on rodent data. |
Frequently Asked Questions: AOD-9604 vs Dulaglutide
What is the difference between AOD-9604 and Dulaglutide?
AOD-9604 is a weight loss peptide that aod-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. the idea was to keep the fat-burning end of growth hormone while leaving out the part that raises igf-1 or messes with blood sugar. it was developed by metabolic pharmaceuticals in australia and tested as an anti-obesity drug, but it is not approved by the fda or any major regulator, and development stopped after it missed its weight-loss targets. Dulaglutide is a weight loss peptide that dulaglutide (brand name trulicity) is a once-weekly injectable glp-1 receptor agonist made by fusing a modified glp-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. it is fda-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. the once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Dulaglutide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Dulaglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Dulaglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Dulaglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.